The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Acceleron Pharma Inc. | COM | 00434H108 | 507 | 19,886 | SH | SOLE | 19,886 | 0 | 0 | ||
Achaogen, Inc. | COM | 004449104 | 33,956 | 2,607,984 | SH | SOLE | 2,607,984 | 0 | 0 | ||
Aclaris Therapeutics, Inc. | COM | 00461U105 | 4,228 | 155,767 | SH | SOLE | 155,767 | 0 | 0 | ||
Aerie Pharmaceuticals, Inc. | COM | 00771V108 | 60,501 | 1,598,452 | SH | SOLE | 1,598,452 | 0 | 0 | ||
Aimmune Therapeutics, Inc. | COM | 00900T107 | 18,485 | 903,890 | SH | SOLE | 903,890 | 0 | 0 | ||
Akari Therapeutics, PLC | SPONSORED ADR | 00972G108 | 1,387 | 197,072 | SH | SOLE | 197,072 | 0 | 0 | ||
Alder BioPharmaceuticals, Inc. | COM | 014339105 | 33,869 | 1,628,328 | SH | SOLE | 1,628,328 | 0 | 0 | ||
Ascendis Pharma A/S | SPONSORED ADR | 04351P101 | 3,643 | 180,000 | SH | SOLE | 180,000 | 0 | 0 | ||
Audentes Therapeutics, Inc. | COM | 05070R104 | 1,216 | 66,553 | SH | SOLE | 66,553 | 0 | 0 | ||
Blueprint Medicines Corporation | COM | 09627Y109 | 8,415 | 300,000 | SH | SOLE | 300,000 | 0 | 0 | ||
Editas Medicine, Inc. | COM | 28106W103 | 4,462 | 274,910 | SH | SOLE | 274,910 | 0 | 0 | ||
Epizyme, Inc. | COM | 29428V104 | 7,323 | 605,239 | SH | SOLE | 605,239 | 0 | 0 | ||
Global Blood Therapeutics, Inc. | COM | 37890U108 | 919 | 63,627 | SH | SOLE | 63,627 | 0 | 0 | ||
Intellia Therapeutics, Inc. | COM | 45826J105 | 9,224 | 703,563 | SH | SOLE | 703,563 | 0 | 0 | ||
iRhythm Technologies, Inc. | COM | 450056106 | 4,986 | 166,210 | SH | SOLE | 166,210 | 0 | 0 | ||
NanoString Technologies, Inc. | COM | 63009R109 | 9,770 | 438,133 | SH | SOLE | 438,133 | 0 | 0 | ||
Orexigen Therapeutics, Inc. | COM | 686164302 | 442 | 254,257 | SH | SOLE | 254,257 | 0 | 0 | ||
Protagonist Therapeutics, Inc. | COM | 74366E102 | 7,615 | 346,281 | SH | SOLE | 346,281 | 0 | 0 | ||
WAVE Life Sciences Ltd. | SHS | Y95308105 | 17,681 | 676,128 | SH | SOLE | 676,128 | 0 | 0 | ||
Zafgen, Inc. | COM | 98885E103 | 1,493 | 469,404 | SH | SOLE | 469,404 | 0 | 0 |